论文部分内容阅读
Gralla 对41例使用顺氯胺铂(cisplatin)120mg/M~2体表面积静注,进行化疗的晚期癌症病者作了双盲法对照组试验。病人分成2组。第1组21例,其中11例使用胃复安2mg/kg 静注,第1次使用的时间是在用顺氯胺铂前30min,然后于注射顺氯胺铂后1.5、3.5、5.5和8.5小时再注射胃复安,达到总量为10mg/kg;另外10例为对照组,使用安慰剂代替胃复安,用法同前。第2组20例,其中10例接受胃复安治疗,方法同前;另10例用甲呱氯丙嗪(prochlorperazine)10mg/
Gralla performed a double-blind, placebo-controlled trial of 41 patients with advanced cancer who received intravenous cisplatin 120 mg/M~2 body surface area for chemotherapy. The patients were divided into 2 groups. The first group consisted of 21 patients, 11 of whom received intravenous metoclopramide at 2 mg/kg. The first time was 30 minutes before the use of cisplatin, and then 1.5, 3.5, 5.5, and 8.5 after the injection of cisplatin. Hours after the injection of metoclopramide to reach a total of 10mg/kg; another 10 cases as the control group, placebo instead of metoclopramide, usage with the previous. The second group of 20 patients, of which 10 cases received metoclopramide therapy, the same method as before; the other 10 cases of prochlorperazine (prochlorperazine) 10mg/